Media Highlights and Announcements

Artrya is in a strong cash position to exploit the power of AI in addressing the largest cause of death in the world – heart disease.

Learn More

Artrya Managing Director and CEO John Barrington AM talks to Proactive about the Salix Coronary Anatomy product successfully gaining European regulatory approval.

Learn More

Following Artrya’s quarterly update to the ASX, Managing Director and CEO John Barrington AM talked about the company’s strategic focus in an interview with Ausbiz.

Learn More

Proactive InvestorsJune 27, 2022

A theatre of human innovation

For medtech entrepreneur and Artrya Ltd CEO John Barrington, every good solution to a problem starts with a clean sheet of paper and a little bit of human ingenuity.

Learn More

Stockhead host Peter Strachan discusses Artrya’s Salix technology and how through the use of big data and AI it can accurately detect markers and indicators of early heart disease.

Learn More

Cardiac software provider Artrya is partnering with Huntsville Heart Center to test the efficacy of its AI-based technology in caring for cardiac patients.

Learn More

Initial agreement includes comparison study of patient cardiac CT scans read by experts to those read by AI-based technology.

Learn More

Under an initial agreement, Huntsville Heart Center and Artyra will compare patient cardiac CT scans read by experts to those read by artificial intelligence (AI)-based technology.

Learn More

Artrya’s MD, John Barrington AM discusses the company’s first US partnership deal with Proactive’s Andrew Scott, detailing a clinical agreement with Huntsville Heart Center.

Learn More

A leading Perth cardiologist believes the recent spate of high-profile heart attacks should sound a warning about the increased health risks associated with modern living.

Learn More